Pacira outlines $725M-$735M revenue target and expands EXPAREL market access while advancing pipeline
Pacira outlines $725M-$735M revenue target and expands EXPAREL market access while advancing pipeline
Homepage   /    business   /    Pacira outlines $725M-$735M revenue target and expands EXPAREL market access while advancing pipeline

Pacira outlines $725M-$735M revenue target and expands EXPAREL market access while advancing pipeline

🕒︎ 2025-11-07

Copyright Seeking Alpha

Pacira outlines $725M-$735M revenue target and expands EXPAREL market access while advancing pipeline

Pacira outlines $725M–$735M revenue target and expands EXPAREL market access while advancing pipeline Nov. 07, 2025 6:16 AM ETPacira BioSciences, Inc. (PCRX) StockAI-Generated Earnings Calls Insights Comments Earnings Call Insights: Pacira BioSciences (PCRX) Q3 2025 Management View CEO Frank Lee reported "another successful quarter of strong execution across our corporate, clinical and commercial initiatives" and highlighted that "year-over-year revenues [are] increasing by 6%, driven by a strong quarter for EXPAREL and iovera." Lee emphasized the Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Quick Insights Pacira acknowledges pricing pressure due to GPO discounting, which has partially offset volume growth; management expects the impact to stabilize after lapping the GPO agreement next year and focuses on closing the gap between volume and sales over time. Key drivers include accelerated EXPAREL volume growth, broader commercial and government reimbursement access, in-licensing of AMT-143 to expand the pain management pipeline, and ongoing commercial investments. Management aims to enhance value through expanding gross margins, executing on revenue growth, share repurchases to reduce share count and boost EPS, disciplined business development, and investing in commercial and product pipeline initiatives. Recommended For You More Trending News

Guess You Like

Who Is Bianca Censori? Everything to Know About Kanye West’s Wife
Who Is Bianca Censori? Everything to Know About Kanye West’s Wife
Kanye “Ye” West and Bianca Cen...
2025-11-01
Informa boss shifts residency to UAE
Informa boss shifts residency to UAE
The boss of a FTSE 100 company...
2025-11-03